Itolizumab, another mab from India, just dropped o
Post# of 148155
(Total Views: 704)
Posted On: 11/25/2020 9:21:27 AM
Itolizumab, another mab from India, just dropped out of the Covid race.
LA JOLLA, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not initiate the EQUINOX Phase 3 clinical trial to evaluate itolizumab in hospitalized COVID-19 patients at this time.
LA JOLLA, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not initiate the EQUINOX Phase 3 clinical trial to evaluate itolizumab in hospitalized COVID-19 patients at this time.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼